Alejandra Palacios, president of the Federal Commission of Economic Competition (COFECE) of Mexico, declared that a lack of competition and abuse of market power by certain pharmaceutical companies in collusion with public authorities has meant that “Mexican households pay an average of 98 percent more than they would pay without surcharges ” when buying medicines.
DUring her participation at a forum on Economic Competition, Palacios denounced public servants and private companies are colluding to carry out acts of corruption in public tenders, leading to overcharges. “When a public servant encourages a particular participant and gives him undue advantages such as privileged information… the companies generate extra-normal profits, which are used to pay these bribes.”
Exposing collusion from the market research stage, Palacios assured that the indicated conducts had damaged public finances by more than 177 million pesos due to these surcharges. Palacios proposed that legislators ” work on a new general law of public contracts, among other subjects, so that the companies that have participated in collusions, which have sold to the government with surcharges, are disqualified for participating.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme
Jan 14, 2025 by
CPI
Apple and Amazon Avoid Mass Lawsuit in UK Over Alleged Collusion
Jan 14, 2025 by
CPI
Top Agent Network Drops Antitrust Suit Against National Association of Realtors
Jan 14, 2025 by
CPI
Weil, Gotshal & Manges Strengthens Antitrust Practice with New Partner
Jan 14, 2025 by
CPI
Russian Court Imposes Hefty Fine on Google for Non-Compliance with Content Removal Orders
Jan 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand